Busulfan Pharmacokinetic Analysis and GST Polymorphism in Adults Undergoing Hematological Stem Cell Transplantation
Status:
Withdrawn
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Between 100 up to 200 adults undergoing HSCT for their primary disease will be included in
this pharmacokinetic/pharmacogenetic study. In the preparative protocol Busulfan (BU)will be
included as indicated in a known protocol. The GST polymorphism (A1,M1,T1 and P1) will be
investigated using real time PCR. A correlation between pharmacokinetic parameters and
patients polymorphism will be performed using known statistical technics for comparison. The
aims of this study are, to correlate the demographic data, clinical presentation, clinical
outcomes of the included individuals, the BU kinetics and the GST polymorphism and to
establish an outcome "map" for those who receive HSCT for their primary disease.